Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 5, 1996, Pages 451-456

  Granvil, Camille P ^a,b   Ducharme, Julie ^b   Leyland Jones, Brian ^b   Trudeau, Marc ^b   Wainer, Irving W ^b,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Enantioselective pharmacokinetics; Ifosfamide enantiomers; Metabolism; N Dechloroethylation

Indexed keywords

DRUG METABOLITE; IFOSFAMIDE; IFOSFAMIDE DERIVATIVE; MESNA; N2 DECHLOROETHYLIFOSFAMIDE; N3 DECHLOROETHYLIFOSFAMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG METABOLISM; ENANTIOMER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; STEREOSPECIFICITY;

ANTINEOPLASTIC AGENTS, ALKYLATING; FEMALE; HUMANS; IFOSFAMIDE; KIDNEY; PELVIC NEOPLASMS; STEREOISOMERISM;

EID: 0030062783     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050411     Document Type: Article

References (20)

1. Allen LM, Creaven PJ (1972) In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes. Cancer Chemother Rep 56: 603-610
2. Allen LM, Creaven PJ (1975) Pharmacokinetics of ifosfamide. Clin Pharmacol Ther 17: 492-498
3. Boos J, Welslau U, Ritter J, Blaschke G, Scellong G (1990) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28: 455-460
4. Brade WP, Herdrich K, Varini M (1985) Ifosfamide pharmacology, safety and therapeutic potential. Cancer Treat Rev 12: 1-47
5. Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629-5637
6. Colvin M (1982) The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol 9 [Suppl 1]: 2-7
7. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M (1973) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 23: 115-129
8. Corlett SA, Parker D, Chrstyn H (1995) Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma. Br J Clin Pharmacol 39: 452-445
9. Crom WR, Kearns CM, Wainer IW, Meyer WH, Pratt CB, Heideman RL, Relling MV (1991) Urinary excretion of ifosfamide enantiomers in children with cancer. Clin Pharmacol Ther 49: 195
10. Gibaldi M, Perrier D (1982) Pharmacokinetics, drugs and the pharmaceutical Sciences 2nd edn. vol 15. Marcel Dekker, New York
11. Granvil CP, Gerhreke B, Konig WA, Wainer IW (1993) The determination of the enantiomers of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in plasma and urine using enantioselective gas chromatography with mass spectrometric detection. J Chromatogr 622: 21-31
12. Granvil CP, Wang T, Batist G, Wainer IW (1994) Influence of phenobarbital induction on the enantioselective N-dechloroethylation of ifosfamide enantiomers in the rat. Drug Metab Dispos 22: 166-168
13. Lewis LD, Fitzgerald DL, Mohan P, Harper PG, Rogers HJ (1990) Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 30: 725-732
14. Lewis LD, Fitzgerald DL, Mohan P, Thatcher PG, Rogers HJ (1991) The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. Br J Clin Pharmacol 31: 77-82
15. Lind MJ, Roberts HL, Thatcher N, Idle JR (1990) The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26: 105-111
16. Lind MJ, Margisson JM, Cerny T, Thatcher N, Wilkinson PM (1990) The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol 30: 140-143
17. Misiura K, Okruszek A, Pankiewicz K, Stec WJ, Czownicki Z, Utracka B (1983) Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine. J Med Chem 26: 674-679
18. Wainer IW, Ducharme J, Granvil CP, Trudeau M, Leyland-Jones B (1994) Ifosfamide stereoselective dechloroethylation and neurotoxicity. Lancet 383: 982-983
19. Wainer IW, Ducharme J, Granvil CP (1996) The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemother Pharmacol 37: 332-336
20. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH, Idle JR (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47: 1157-1161